12
Diagnosis
Table 2. Selected Genetic Alterations Linked to FDA
Approvals as of June 2021
a
Genetic Alterations Tumor type Targeted Therapeutics
FDA-approved treatments for specific genetic alterations in specific tumor types (cont'd)
EGFR exon 19 deletion,
L858R
NSCLC
Afatinib, Dacomitinib,
Erlotinib, Gefitinib, Osimertinib
EGFR exon 20
insertions
Amivantamab
EGFR non-resistant
mutations other than
exon 19 deletions and
L858R
Afatinib
EGFR T790M
Osimertinib
ERBB2 amplification Breast cancer Ado-Trastuzumab Emtansine,
Capecitabine + Trastuzumab
+ Tucatinib, Neratinib,
Pertuzumab + Trastuzumab,
Trastuzumab, Trastuzumab
Deruxtecan
Esophagogastric cancer Trastuzumab
Gastric cancer,
gastroesophageal junction
cancer
Trastuzumab Deruxtecan
FGFR2 fusions Bladder cancer Erdafitinib
Cholangiocarcinoma Pemigatinib, Infigratinib
FGFR3 fusions Bladder cancer Erdafitinib
Oncogenic mutations
in FGFR3
GIS positive and/or
HRD positive
Ovarian cancer Niraparib
KRAS G12C NSCLC Sotorasib
MET exon 14 skipping NSCLC Capmatinib, Tepotinib
dMMR and/or MSI-H Colorectal cancer Ipilimumab + Nivolumab,
Nivolumab
Endometrial cancer Dostarlimab
(cont'd)
